Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital declines year over year
Q1 FY2026 other working capital of $1.48M (cash outflow) fell 43.5% year over year, ahead of the -58.2% change in trailing-twelve-month other working capital. Sequentially, it rose 500.8% from the prior quarter. Over 3 fiscal years it compounded at +238.4% a year.
Context
- Other working capital grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -43.5% holds above the trailing-twelve-month pace of -58.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (3.45M) USD
- Year-over-year change
- -183.4%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.45M) | -183.4% |
| FY2024 | 2024-12-31 | (1.22M) | +11.1% |
| FY2023 | 2023-12-31 | (1.37M) | -1438.2% |
| FY2022 | 2022-12-31 | (89K) | +93.4% |
| FY2021 | 2021-12-31 | (1.35M) | — |
Other Working Capital vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -58.2% is the 7th highest of 10, against a peer median of +47.4%.
- Over three fiscal years its annual growth of +238.4% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.48M USD | +512.3% | — | 418.8% | |
| LTM Mar 2026 | $6.51M USD | -4.9% | -59.0% | — | |
| LTM Mar 2026 | $3.71M USD | +222.5% | — | — | |
| LTM Mar 2026 | $2.31M USD | -58.2% | +238.4% | — | |
| LTM Mar 2026 | $2.06M USD | +58.6% | +2.8% | 0.8% | |
CBUSCibus, Inc. | LTM Mar 2026 | $2.04M USD | -145.3% | — | 47.5% |
| LTM Mar 2026 | $1.75M USD | +147.5% | — | — | |
| LTM Mar 2026 | $743K USD | -92.3% | +8.4% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$708.86K CAD | +47.4% | — | 3.9% |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $593K USD | -165.7% | +45.5% | — |
| Peer median (excluding UNCY) | — | +47.4% | +5.6% | 25.7% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 966K | 1.05M | 1.77M | 2.35M | 2.64M |
| Change in Working Capital | (105K) | 1.18M | (93K) | (427K) | (5.95M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.24M | 1.27M | 1.28M | 790K | (2.51M) |
| Other Working Capital | (1.35M) | (89K) | (1.37M) | (1.22M) | (3.45M) |
| Other Non-Cash Items | 3.38M | 21K | 10.3M | 5.8M | (2.02M) |
| Operating Cash Flow | (5.77M) | (15.65M) | (18.28M) | (28.58M) | (31.32M) |
| Capital Expenditures | (29K) | (2K) | (12K) | (72K) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (12.07M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (29K) | (2K) | (12K) | (72K) | (12.1M) |
| Debt Repayment | (15K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 22.27M | 11K | 0 | 683K | 48.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.1M) | 0 |
| Other Financing Activities | 119K | (482K) | (2.65M) | (4.5M) | (1.61M) |
| Financing Cash Flow | 22.38M | (471K) | 27.54M | 45.09M | 46.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.58M | (16.12M) | 9.25M | 16.44M | 3.06M |
| Free Cash Flow | (5.8M) | (15.65M) | (18.3M) | (28.65M) | (31.34M) |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.